The
tumor-associated
antigen mucin 1 (MUC1) has been pursued as an attractive target for
cancer immunotherapy, but the poor immunogenicity of the endogenous
antigen hinders the development of
vaccines capable of inducing effective anti-MUC1 immunodominant responses. Herein, we prepared synthetic anti-MUC1
vaccines in which the hydrophilic MUC1
antigen was N-terminally conjugated to one or two palmitoyl
lipid chains (to form amphiphilic Pam-MUC1 or
Pam2 -MUC1). These amphiphilic
lipid-tailed MUC1
antigens were self-assembled into
liposomes containing the NKT cell agonist αGalCer as an adjuvant. The
lipid-conjugated
antigens reshaped the physical and morphological properties of liposomal
vaccines. Promising results showed that the anti-MUC1
IgG antibody titers induced by the
Pam2 -MUC1
vaccine were more than 30- and 190-fold higher than those induced by the Pam-MUC1
vaccine and the MUC1
vaccine without
lipid tails, respectively. Similarly,
vaccines with the TLR1/2 agonist Pam3 CSK4 as an adjuvant also induced conjugated
lipid-dependent immunological responses. Moreover,
vaccines with the αGalCer adjuvant induced significantly higher titers of
IgG antibodies than
vaccines with the Pam3 CSK4 adjuvant. Therefore, the non-covalent assembly of the amphiphilic lipo-MUC1
antigen and the NKT cell agonist αGalCer as a
glycolipid adjuvant represent a synthetically simple but immunologically effective approach for the development of anti-MUC1
cancer vaccines.